Lord Freyberg – 2016 Parliamentary Question to the Department of Health

The below Parliamentary question was asked by Lord Freyberg on 2016-02-08.

To ask Her Majesty’s Government, further to the Written Answer by Lord Prior of Brampton on 4 February (HL5345), how many of the 20 patients with reports issued so far by the Genomic England cancer project had (1) a clinically actionable mutation for which the NHS will reimburse the costs of the treatment drug, and (2) a clinically actionable mutation for any trial currently open in the UK; and of those patients in both categories, how many had a clinically actionable mutation in open reading frames that would be covered by a simple next-generation sequencing panel test.

Lord O’Neill of Gatley

In 2006 the United Nations imposed restrictions on a range of goods from entering or leaving North Korea and imposed a travel ban and asset freeze against those persons designated as persons who engage in or provide support for North Korea’s nuclear-related, other weapons of mass destruction related and ballistic missile-related programmes. These restrictions were implemented in the EU in 2007, and have subsequently been expanded by the EU.

Under the current EU Regulation, UK financial institutions are able to establish banking relationships with North Korean banking institutions if there are no reasonable grounds to believe this will contribute to North Korea’s nuclear-related, other weapons of mass destruction related or ballistic missile-related programmes. In practice, there are almost no financial links between the UK and North Korea. North Korea is almost wholly dependent on China for international assistance.